Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
Steven E. Nissen(Cleveland Clinic), Laurent Kassalow(Daiichi Sankyo (Germany)), İlke Sipahi(Cleveland Clinic), John Deanfield(Universidad de Londres), Stephen J. Nicholls(Australian Centre for Heart Health), James Hanyok(Daiichi Sankyo (United States)), David D. Waters(San Francisco General Hospital), Paul Schoenhagen(Cleveland Clinic), Peter Ganz(San Francisco General Hospital), Michael H. Davidson(Kiadis Pharma (Netherlands)), H. Bryan Brewer(Altrincham Hospital), Tim Crowe(Cleveland Clinic), L Wiśniewski(Cleveland Clinic), Carl J. Pepine(Cedars-Sinai Medical Center), E. Murat Tuzcu(Cleveland Clinic)
Cited by 397
Related Papers
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
|The Lancet|1992|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery
|Journal of the American College of Cardiology|2002|4.6k